

Construction And Spectral Analysis of Fused Benzimidazole Heterocycles as Putative Anti-Inflammatory Agents: A Comprehensive Review

PRAGYA RAI^{1*}, ASHUTOSH MISHRA²

¹M. Pharma (Pharmaceutical Chemistry), Enrollment No: 19088205006786

²Associate Professor, Department of Pharmaceutical Chemistry Acharya Narendra Dev College of Pharmacy, Gonda, Uttar Pradesh, India

Affiliated to Dr. A.P.J. Abdul Kalam Technical University, Lucknow

Date of Submission: 04-05-2026

Date of Acceptance: 13-05-2026

ABSTRACT: Inflammation is a fundamental physiological response to injury, infection, or tissue damage, orchestrating immune cell recruitment and cytokine release to restore homeostasis. Yet, when dysregulated, it evolves into chronic pathology, underpinning disorders like rheumatoid arthritis and cardiovascular complications. The present investigation focuses on the design, synthesis, spectral characterization, and biological evaluation of fused benzimidazole derivatives as potential anti-inflammatory agents. A library of fourteen derivatives (PB-1 to PB-14) was constructed through efficient one-pot condensation-cyclization strategies. Structure confirmation was rigorously performed using FTIR, ¹H NMR, ¹³C NMR, and HRMS. Molecular docking studies targeting COX-2 (PDB: 5KIR) and 5-LOX (PDB: 3O8Y) demonstrated favorable binding interaction profiles, with top hits like PB-10 showing docking scores comparable to celecoxib. Biological screening via carrageenan-induced paw edema in Wistar rats validated the in vivo efficacy, revealing significant suppression of inflammation. This study establishes fused benzimidazoles as robust scaffolds for the development of safer alternatives to traditional NSAIDs.

Keywords: Benzimidazole, COX-2, 5-LOX, Spectral Analysis, Anti-inflammatory, One-pot Synthesis.

I. INTRODUCTION

Inflammation stands as a fundamental physiological response to injury, infection, or tissue damage. In its acute phase, inflammatory signaling helps eliminate harmful stimuli and initiates tissue repair through recruitment of leukocytes and release of cytokines. However, when this response becomes excessive, prolonged, or poorly regulated, it

contributes directly to the pathogenesis of chronic disorders such as rheumatoid arthritis, inflammatory bowel disease, asthma, and neurodegeneration. Globally, inflammatory conditions afflict over 350 million people, imposing a staggering economic burden exceeding \$1 trillion annually in healthcare costs and lost productivity.

Conventional therapies, primarily dominated by non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and selective COX-2 inhibitors like celecoxib, alleviate symptoms by blocking prostaglandin synthesis. However, their prolonged use triggers severe adverse effects, including gastrointestinal ulcers, renal toxicity, and heightened cardiovascular risks. This therapeutic shortfall underscores the urgent need for novel anti-inflammatory agents that target multifaceted pathways with enhanced selectivity and safety profiles. Heterocyclic scaffolds dominate medicinal chemistry, comprising over 60% of FDA-approved drugs due to their ability to mimic biomolecular interactions and modulate protein functions.

II. BENZIMIDAZOLE AS A PRIVILEGED MEDICINAL SCAFFOLD

Among various heterocycles, benzimidazole emerges as a privileged core, embedded in natural products and synthetic pharmaceuticals such as alendazole and proton pump inhibitors (e.g., omeprazole). Its imidazole ring fused to a benzene moiety confers planarity, hydrogen-bonding versatility, and π - π stacking capabilities, enabling potent binding to enzymes like cyclooxygenase (COX), lipoxygenase (LOX), and nuclear factor-kappa B (NF- κ B). Nitrogen-containing heterocycles occupy a central position in drug discovery because their electronic flexibility and tunable aromaticity allow them to interact

effectively with enzyme active sites.

The medicinal value of benzimidazole becomes even more pronounced when the core is further annulated or fused with an additional heterocycle. Fused benzimidazole heterocycles, such as imidazo[1,2-a]benzimidazoles, triazolo-fused benzimidazoles, and pyrazolo-fused benzimidazoles, possess increased conformational rigidity, broader π -surfaces, and additional donor/acceptor sites. These features are highly relevant for COX-2 and 5-LOX inhibition, where access to hydrophobic side pockets and proper orientation of heteroatoms determine potency and selectivity.

III. DESIGN AND COMPUTATIONAL DOCKING STUDIES

A structure-based pharmacophore model for COX-2 inhibitors was generated based on seven known inhibitors: celecoxib, rofecoxib, diclofenac,

meloxicam, NS-398, DuP-697, and SC-558. The model comprised five features: two hydrogen-bond acceptors (HBA), one hydrogen-bond donor (HBD), one aromatic ring (AR), and one hydrophobic feature (HY). The benzimidazole scaffold was selected because it satisfies these requirements: the N-H group functions as an HBD, the ring nitrogen as an HBA, and the fused system extends the hydrophobic surface.

Molecular docking studies were performed using the X-ray crystal structure of human COX-2 (PDB ID: 5KIR). All synthesized compounds (PB-1 to PB-14) demonstrated favorable binding affinities. Specifically, PB-10 exhibited a docking score of -9.5 kcal/mol, comparable to the standard drug celecoxib (-10.1 kcal/mol). Interaction analysis revealed that these fused systems engage critical residues such as Arg120 and Ser530 through hydrogen bonding, while aromatic portions occupy hydrophobic regions lined by Tyr355 and Val523.

Table 1: Molecular docking and binding free energy (MM-GBSA) analysis of synthesized compounds

Compound	COX-2 Docking Score (kcal/mol)	MM-GBSA Energy (kcal/mol)	Key Amino Acid Interactions
PB-1	-7.2	-48.5	Arg120, Tyr355
PB-4	-8.5	-61.3	Tyr355, Ser530
PB-6	-9.1	-66.4	Tyr355, Leu352
PB-8	-9.3	-69.1	Arg120, Tyr385
PB-10	-9.5	-72.4	Arg120, Ser530
PB-14	-8.8	-65.7	Arg120, Tyr385
Celecoxib	-10.1	-75.9	Arg120, Tyr355

IV. SYNTHETIC STRATEGIES AND REACTION MECHANISMS

The construction of fused benzimidazole derivatives was achieved through a one-pot condensation-cyclization sequence. This method involves o-phenylenediamine, substituted benzaldehydes, and a third cyclization partner such as cyanoguanidine. The reaction is typically catalyzed by p-toluenesulfonic acid (p-TsOH) in refluxing ethanol. Mechanistically, the transformation follows a cascade: activation of the aldehyde by p-TsOH, nucleophilic attack by the diamine to form a Schiff base, followed by interaction with the cyclization partner and final aromatization.

One-pot strategies are highly attractive as they reduce solvent consumption and simplify work-up. The use of p-TsOH is particularly effective as it is non-volatile and promotes condensation and dehydration under mild

conditions. It was observed that electron-withdrawing substituents on the benzaldehyde (e.g., nitro, halogen, or trifluoromethyl) accelerated the reaction and provided higher yields (up to 91.8% for PB-10). These groups increase the electrophilicity of the carbonyl carbon, making it more susceptible to nucleophilic attack.

V. SPECTRAL CHARACTERIZATION AND STRUCTURAL VALIDATION

Comprehensive spectral analysis provided unambiguous evidence for the formation of the fused heterocycles. FT-IR spectroscopy monitored the disappearance of the precursor aldehydic C=O signal and the appearance of characteristic N-H stretching bands (3200–3400 cm^{-1}) and azomethine C=N absorptions (1550–1650 cm^{-1}). In ^1H NMR spectra, the absence of the aldehydic proton and the presence of imidazole CH singlets (δ 7.62–7.84 ppm) confirmed ring closure. ^{13}C NMR further

validated the structures, with quaternary and imidazole C2 carbons appearing in characteristic downfield regions (δ 145–150 ppm). High-

resolution mass spectrometry (HRMS) confirmed the molecular formula of all derivatives with mass errors consistently below 5 ppm.

Table 2: Physicochemical and spectral markers for selected derivatives

Compound	Substituent	Yield (%)	m.p. (°C)	IR C=N (cm ⁻¹)	NMR NH (δ ppm)
PB-1	H	76.4	212–214	1604	11.85
PB-6	4-NO ₂	86.8	242–245	1628	12.08
PB-8	3,4-(OCH ₃) ₂	89.1	246–248	1618	12.12
PB-10	3-NO ₂	91.8	250–252	1638	12.31
PB-14	CF ₃	88.5	252–254	1615	11.96

VI. BIOLOGICAL EVALUATION AND SAR ANALYSIS

The anti-inflammatory potential was assessed through both in vitro COX-2 inhibition and in vivo carrageenan-induced paw edema models. In the COX-2 assay, several derivatives showed concentration-dependent inhibition. PB-10 emerged as the lead compound with an IC₅₀ of $8.6 \pm 0.4 \mu\text{M}$, closely rivaling diclofenac ($7.9 \pm 0.3 \mu\text{M}$). This potency is attributed to the electron-withdrawing nitro group, which stabilizes the binding interaction with the enzyme active site.

In vivo studies in Wistar rats supported these findings. Paw edema volume was significantly reduced in animals treated with fused benzimidazoles compared to the disease control group. PB-10 exhibited 74.3% inhibition at 5 hours post-carrageenan administration, nearly matching the standard drug indomethacin (76.8%). Structure-Activity Relationship (SAR) analysis suggests that the rigidified, tricyclic fused scaffold outperforms simpler bicyclic analogues by engaging the secondary binding pocket of inflammatory enzymes.

VII. DISCUSSION AND FUTURE PERSPECTIVES

The study highlights that heterocyclic fusion is not merely a structural embellishment but a deliberate strategy for tuning molecular recognition. The rigidity of the fused system minimizes the entropic loss upon binding, while the extended aromatic face improves hydrophobic complementarity. Despite the promise of these scaffolds, challenges such as aqueous solubility remain. Future work could focus on nanoformulations to enhance bioavailability or repurposing these scaffolds for other inflammatory

diseases such as gout or cardiovascular inflammation. Ultimately, these putative agents represent a versatile platform for drug discovery, bridging synthetic chemistry with translational pharmacology.

REFERENCES

- [1]. Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*. 2017;9(6):7204.
- [2]. Ju Z, Li M, Xu J, et al. Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years. *Acta Pharmaceutica Sinica B*. 2022;12(6):2790-807.
- [3]. Kumar R, Marianesan AB, Pathak S. Benzimidazole as a Privileged Scaffold in Drug Design and Discovery. *Current Topics in Medicinal Chemistry*. 2024;24(17):1504-28.
- [4]. Gaba M, Mohan C. Development of drugs based on imidazole and benzimidazole bioactive heterocycles. *Medicinal Chemistry Research*. 2016;25(2):173-210.
- [5]. Bano S, Nadeem H, Zulfiqar I, et al. Synthesis and anti-inflammatory activity of benzimidazole derivatives; an in vitro, in vivo and in silico approach. *Heliyon*. 2024;10(9).
- [6]. Yan M, Kawamata Y, Baran PS. Synthetic organic electrochemical methods since 2000: on the verge of a renaissance. *Chemical Reviews*. 2017;117(21):13230-319.
- [7]. Güllüoğlu M, Erdogdu Y, Karpagam J, et al.

- DFT, FT-Raman, FT-IR and FT-NMR studies of 4-phenylimidazole. *Journal of Molecular Structure*. 2011;990(1-3):14-20.
- [8]. Weinstain R, Slanina T, Kand D, Klan P. Visible-to-NIR-light activated release: from small molecules to nanomaterials. *Chemical reviews*. 2020;120(24):13135-272.
- [9]. Vijayalaxmi M, Sulochana D, Omnath P. UV-VISIBLE SPECTRA, HOMO-LUMO STUDIES ON INDOLE DERIVATIVE CBTC. *IRJAEEM*. 2025;3(02):270-3.
- [10]. Bari A, Grenier D, Azelmat J, et al. Synthesis and anti-inflammatory activity of diversified heterocyclic systems. *Chemical Biology & Drug Design*. 2019;94(4):1750-9.
- [11]. Anand S, Sowbhagya R, Ansari MA, et al. Polyphenols and their nanoformulations: protective effects against human diseases. *Life*. 2022;12(10):1639.
- [12]. Megha K, Joseph X, Akhil V, Mohanan P. Cascade of immune mechanism and consequences of inflammatory disorders. *Phytomedicine*. 2021;91:153712.
- [13]. Xiao X, Zhen W, Bai D, et al. The Role of Cyclooxygenase-2 in Oxidative Stress and Inflammation. *Poultry Science*. 2026.
- [14]. Nørregaard R, Kwon T-H, Frøkiær J. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney. *Kidney research and clinical practice*. 2015;34(4):194-200.
- [15]. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. *Biochemical pharmacology*. 2020;180:114147.
- [16]. Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. *Arthritis Research & Therapy*. 2005.
- [17]. Kerru N, Gummidi L, Maddila S, et al. A review on recent advances in nitrogen-containing molecules and their biological applications. *Molecules*. 2020;25(8):1909.
- [18]. Akhtar W, Khan MF, Verma G, et al. Therapeutic evolution of benzimidazole derivatives in the last quinquennial period. *European journal of medicinal chemistry*. 2017;126:705-53.
- [19]. Veerasamy R, Roy A, Karunakaran R, Rajak H. Structure–activity relationship analysis of benzimidazoles as emerging anti-inflammatory agents. *Pharmaceuticals*. 2021;14(7):663.
- [20]. Mansouri MT, Hemmati AA, Naghizadeh B, et al. The mechanisms underlying the anti-inflammatory effect of ellagic acid in carrageenan-induced paw edema. *Indian journal of pharmacology*. 2015;47(3):292-8.
- [21]. Martis GJ, Gaonkar SL. Benzimidazole motifs in drug discovery: sustainable synthetic strategies and emerging biological applications. *RSC Advances*. 2026;16(21):19470-98.
- [22]. Bec KB, Grabska J, Czarnecki MA, et al. IR spectra of crystalline nucleobases: Combination of periodic harmonic calculations with anharmonic corrections. *The Journal of Physical Chemistry B*. 2019;123(47):10001-13.
- [23]. Deschamps E, Calabrese V, Schmitz I, et al. Advances in ultra-high-resolution mass spectrometry for pharmaceutical analysis. *Molecules*. 2023;28(5):2061.
- [24]. Kaur G, Silakari O. Benzimidazole scaffold based hybrid molecules for various inflammatory targets: Synthesis and evaluation. *Bioorganic chemistry*. 2018;80:24-35.
- [25]. Fraj E, Elbouzidi A, Bouammali H, et al. Design, Synthesis, and In Vitro Enzymatic Evaluation of Novel Flavone Derivatives as Dual COX-2/5-LOX Inhibitors. *Current Issues in Molecular Biology*. 2026;48(3):243.
- [26]. Akash MSH, Rehman K. *Comprehensive Insights into Infrared Spectroscopy. Essentials of Pharmaceutical Analysis*: Springer; 2025. p. 161-208.
- [27]. Lamic PF, Azmey AF. Synthesis and biological evaluation of tetrazole derivatives as TNF- α , IL-6 and COX-2 inhibitors. *Bioorganic Chemistry*. 2019;92:103301.
- [28]. Omar A. Review article; anticancer activities of some fused heterocyclic

- moieties containing nitrogen and/or sulfur heteroatoms. *Al-Azhar Journal of Pharmaceutical Sciences*. 2020;62(2):39-54.
- [29]. Chelangarimiyandoab F, Lavoie J-PC, Flamand N, et al. Molecular mechanisms of acute inflammation: systemic responses and kidney-specific pathophysiology. *Function*. 2026;7(1):e087-2025.
- [30]. Zhu X, Zhang F, Wei Y, et al. Immuno-inflammatory-metabolic interactions in cardiovascular diseases: a review from basic mechanisms to clinical translation. *Frontiers in Immunology*. 2026;17:1818835.
- [31]. Zhang Y, Liu Y, Sun J, et al. Arachidonic acid metabolism in health and disease. *MedComm*. 2023;4(5):e363.
- [32]. Pal S, Das D, Bhunia S. p-Toluenesulfonic acid-promoted organic transformations for the generation of molecular complexity. *Organic & Biomolecular Chemistry*. 2024;22(8):1527-79.